Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
An angiotensin IV analog peptide developed at Washington State University that has shown extraordinary cognitive-enhancing properties in animal models. In preclinical studies, dihexa was reported to be up to 10 million times more potent than BDNF at promoting new synapse formation, making it one of the most discussed nootropic peptides in the biohacking community.
A synthetic heptapeptide analog of ACTH(4-10) developed in Russia, where it has been used clinically for decades to treat cerebral ischemia and cognitive impairment. Growing interest in the West for nootropic and neuroprotective applications.
Binds to hepatocyte growth factor (HGF) receptor (c-Met), potentiating HGF/c-Met signaling which promotes synaptogenesis, dendritic spine formation, and neuronal connectivity. This mechanism is distinct from traditional nootropics and operates through growth factor pathways rather than neurotransmitter modulation.
Activates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival, synaptic plasticity, and cognitive function. Also modulates serotonergic, dopaminergic, and adrenergic systems. Reduces oxidative stress and neuroinflammation.
- Cognitive enhancement (investigational)
- Memory and learning support
- Neuroprotection research
- Alzheimer's disease research
- Cognitive enhancement and focus
- Neuroprotection after stroke or ischemia
- Anxiety and depression support
- ADHD symptom management
- Memory and learning improvement
- No human clinical trials — safety profile unknown
- Theoretical cancer risk (HGF/c-Met pathway involved in tumor growth)
- Long-term effects completely unstudied in humans
- Quality control concerns with research chemical sourcing
- Limited Western clinical trial data
- Nasal spray form may cause irritation
- Potential stimulant-like effects
- Headaches reported
- Long-term safety profile unknown in Western populations
No FDA status. Purely a research compound with preclinical data only. No IND application or clinical trials registered. Available only as a research chemical. The HGF/c-Met mechanism raises theoretical oncology concerns that would need to be addressed before clinical development.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Has extensive clinical use in Russia for cerebral ischemia and trigeminal neuralgia, but limited US clinical trial data. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.